Ex Vivo Activated T-Cell Composition for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive T-cell therapies for cancer treatment face inefficiencies due to inconsistent activation levels and variability in lymphocytic cell compositions, leading to suboptimal targeting of tumor-associated antigens and potential off-target effects.
Innovation Solution
A T-cell composition with a fixed ratio of ex vivo activated lymphocytic subsets, each specific to a single tumor-associated antigen, is administered, where each subset is primed with specific peptide epitopes matching the patient's tumor profile, enhancing targeting specificity and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T-cells are collected from patient or donor and stimulated with antigen presenting cells bearing tumor antigens, then the immune system's ability to fight disease is bolstered, but the activation levels and lymphocytic cell compositions become inconsistent and variable
Solution Approach 1:
The patent applies parameter changes by standardizing the activation conditions and composition ratios of T-cell subsets. Specifically, it defines fixed ratios for different lymphocytic subsets (CD8+ T-cells, CD4+ T-cells, NK cells, gamma delta T-cells) and controls activation parameters to achieve consistent therapeutic compositions across different patients and donors, thereby resolving the contradiction between reliability and variability
Solution Approach 2:
The patent applies local quality by differentiating and standardizing specific subsets of lymphocytic cells with distinct functions. Each subset (CD8+ cytotoxic T-cells, CD4+ helper T-cells, NK cells, gamma delta T-cells) is controlled to maintain specific ratio ranges, allowing each subset to contribute its unique anti-tumor activity while maintaining overall composition consistency, thus resolving the variability issue
2Reliability
If T-cells are expanded ex vivo and administered to patient, then immune response against tumor is enhanced, but off-target effects may occur due to poor targeting specificity
Solution Approach 1:
The patent applies parameter changes by optimizing the ratio parameters of different T-cell subsets to enhance targeting specificity. By controlling the proportions of CD8+ T-cells (0.2-0.8), CD4+ T-cells (0.1-0.5), NK cells (0.05-0.3), and gamma delta T-cells (0.05-0.3), the composition achieves improved tumor targeting while minimizing off-target effects through balanced immune response
3Manufacturing precision
If standardized fixed ratio of lymphocytic subsets is used, then consistency and targeting efficacy are improved, but the complexity of manufacturing and characterizing the composition increases
Solution Approach 1:
The patent applies parameter changes by establishing specific numerical ranges for each lymphocytic subset ratio, which simplifies the manufacturing process by providing clear targets for cell separation and recombination. The defined ranges (CD8+ T-cells: 0.2-0.8, CD4+ T-cells: 0.1-0.5, NK cells: 0.05-0.3, gamma delta T-cells: 0.05-0.3) enable standardized production while maintaining manufacturing precision
Solution Approach 2:
The patent applies segmentation by dividing the T-cell composition into distinct functional subsets that are separately isolated and then recombined in controlled ratios. This segmentation approach (separating CD8+ T-cells, CD4+ T-cells, NK cells, and gamma delta T-cells) simplifies the manufacturing process by allowing independent control of each subset while achieving overall composition consistency
Data Source
AI summary
The disclosure provides T-cell compositions, therapies and processes of manufacture that are tailored to the specific antigenic expression of a subjects' tumor and allowing for changes in expression over time based on either pressure from antineoplastic therapy or natural heterogeneous selection. The disclosure also extends to methods of manufacturing such T-cell compositions and the generation of single antigen T-cell banks from healthy donors to provide an improved personalized T-cell therapy.